5-(5-phenyl-4-((pyridin-2-ylmethyl)amino)quinazolin-2-yl)pyridin-2(1H)-one

ID: ALA4081790

Chembl Id: CHEMBL4081790

PubChem CID: 51030732

Max Phase: Preclinical

Molecular Formula: C25H19N5O

Molecular Weight: 405.46

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Oc1ccc(-c2nc(NCc3ccccn3)c3c(-c4ccccc4)cccc3n2)cn1

Standard InChI:  InChI=1S/C25H19N5O/c31-22-13-12-18(15-27-22)24-29-21-11-6-10-20(17-7-2-1-3-8-17)23(21)25(30-24)28-16-19-9-4-5-14-26-19/h1-15H,16H2,(H,27,31)(H,28,29,30)

Standard InChI Key:  KITYXUGKWPDMSJ-UHFFFAOYSA-N

Associated Targets(Human)

KCNA5 Tclin Voltage-gated potassium channel subunit Kv1.5 (1353 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 405.46Molecular Weight (Monoisotopic): 405.1590AlogP: 5.07#Rotatable Bonds: 5
Polar Surface Area: 83.82Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: 1HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 11.07CX Basic pKa: 4.67CX LogP: 5.39CX LogD: 5.39
Aromatic Rings: 5Heavy Atoms: 31QED Weighted: 0.42Np Likeness Score: -1.34

References

1. Gunaga P, Lloyd J, Mummadi S, Banerjee A, Dhondi NK, Hennan J, Subray V, Jayaram R, Rajugowda N, Umamaheshwar Reddy K, Kumaraguru D, Mandal U, Beldona D, Adisechen AK, Yadav N, Warrier J, Johnson JA, Sale H, Putlur SP, Saxena A, Chimalakonda A, Mandlekar S, Conder M, Xing D, Gupta AK, Gupta A, Rampulla R, Mathur A, Levesque P, Wexler RR, Finlay HJ..  (2017)  Selective IKur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide.,  60  (9): [PMID:28418664] [10.1021/acs.jmedchem.6b01889]
2. Finlay HJ, Johnson JA, Lloyd JL, Jiang J, Neels J, Gunaga P, Banerjee A, Dhondi N, Chimalakonda A, Mandlekar S, Conder ML, Sale H, Xing D, Levesque P, Wexler RR..  (2016)  Discovery of 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a Potent I Kur Inhibitor.,  (9): [PMID:27660686] [10.1021/acsmedchemlett.6b00117]

Source